EUVIMEDOpdag EUVIMED
CrossrefInfokort

Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer (ED‐SCLC): A systematic review and meta‐analysis of randomized controlled trials

Zeeshan Afzal, Sara Hira, Xia Song, Na Wang

Malignancy Spectrum · 2024

DOI: 10.1002/msp2.46 ↗
AbstractBibliografiske oplysninger

Abstract

Abstract Background Platinum‐based chemotherapy in addition to the non‐platinum agent etoposide is the standard of care for extensive‐stage small cell lung cancer (ES‐SCLC). However, the front‐line chemotherapy regimen is not known. Therefore, we aimed to perform this review comparing irinotecan/carboplatin (IC) and etoposide/carboplatin (EC) in patients of extended disease small cell lung cancer (ED‐SCLC). Methods We searched three databases, that is, PubMed, Embase, and Cochrane Library. The outcomes for complete response (CR), median overall survival (OS), and progression‐free survival (PFS) were evaluated. In addition, adverse events such as leukopenia, thrombocytopenia, anemia, diarrhea, and infections were also assessed. RevMan 5.4.1 was used to perform the statistical analysis. Results Three randomized controlled trials (RCTs) with 676 patients were included. There was a significant difference between IC and EC arms in terms of CR (risk ratio [RR] = 2.52; 95% confidence interval [CI]: 1.20−5.32; p = 0.02, I 2 (i.e., the percentage of the total variance that is due to between‐study heterogeneity) = 0%), leukopenia (RR = 0.47; 95% CI: 0.23−0.97; p = 0.04; I 2 = 90%), amimia (RR = 0.55; 95% CI: 0.38−0.78; p = 0.0008; I 2 = 0%), thrombocytopenia (RR = 0.51; 95% CI: 0.39–0.68; p = 0.00001; I 2 = 0%), and diarrhea (RR = 4.88; 95% CI: 1.64−14.49; p = 0.004; I 2 = 33%). There was no statistically significant difference between IC and EC arms in terms of median OS (hazard ratio [HR] = 1.16; 95% CI: 0.84−1.62; p = 0.37; I 2 = 74%), PFS (HR = 1.04; 95% CI: 0.69−1.56; p = 0.85; I 2 = 77%), nausea (RR = 1.70; 95% CI: 0.76−3.81; p = 0.19; I 2 = 0%), infection (RR = 0.97; 95% CI: 0.64−1.48; p = 0.89; I 2 = 0%), and treatment‐related deaths (RR = 0.58; 95% CI: 0.24−1.42; p = 0.23; I 2 = 0%). Conclusion This meta‐analysis provides valuable evidence supporting the superiority of IC regimens over EC regimens in terms of CR and toxicity profile for ED‐SCLC.

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.

Se priser →